374 related articles for article (PubMed ID: 30813247)
21. The amino terminus of varicella-zoster virus (VZV) glycoprotein E is required for binding to insulin-degrading enzyme, a VZV receptor.
Li Q; Krogmann T; Ali MA; Tang WJ; Cohen JI
J Virol; 2007 Aug; 81(16):8525-32. PubMed ID: 17553876
[TBL] [Abstract][Full Text] [Related]
22. Baculovirus Display of Varicella-Zoster Virus Glycoprotein E Induces Robust Humoral and Cellular Immune Responses in Mice.
Xue W; Li T; Zhang S; Wang Y; Hong M; Cui L; Wang H; Zhang Y; Chen T; Zhu R; Chen Z; Zhou L; Zhang R; Cheng T; Zheng Q; Zhang J; Gu Y; Xia N; Li S
Viruses; 2022 Aug; 14(8):. PubMed ID: 36016407
[TBL] [Abstract][Full Text] [Related]
23. Enhanced Potency and Persistence of Immunity to Varicella-Zoster Virus Glycoprotein E in Mice by Addition of a Novel BC02 Compound Adjuvant.
Li J; Fu L; Yang Y; Wang G; Zhao A
Vaccines (Basel); 2022 Mar; 10(4):. PubMed ID: 35455278
[TBL] [Abstract][Full Text] [Related]
24. Characterization of host-cell line specific glycosylation profiles of early transmitted/founder HIV-1 gp120 envelope proteins.
Go EP; Liao HX; Alam SM; Hua D; Haynes BF; Desaire H
J Proteome Res; 2013 Mar; 12(3):1223-34. PubMed ID: 23339644
[TBL] [Abstract][Full Text] [Related]
25. Opposite immune reactivity of serum IgG and secretory IgA to conformational recombinant proteins mimicking V1/V2 domains of three different HIV type 1 subtypes depending on glycosylation.
Granados-Gonzalez V; Claret J; Berlier W; Vincent N; Urcuqui-Inchima S; Lucht F; Defontaine C; Pinter A; Genin C; Riffard S
AIDS Res Hum Retroviruses; 2008 Feb; 24(2):289-99. PubMed ID: 18260782
[TBL] [Abstract][Full Text] [Related]
26. Targeting host O-linked glycan biosynthesis affects Ebola virus replication efficiency and reveals differential GalNAc-T acceptor site preferences on the Ebola virus glycoprotein.
Bagdonaite I; Abdurahman S; Mirandola M; Pasqual D; Frank M; Narimatsu Y; Joshi HJ; Vakhrushev SY; Salata C; Mirazimi A; Wandall HH
J Virol; 2024 Jun; 98(6):e0052424. PubMed ID: 38757972
[TBL] [Abstract][Full Text] [Related]
27. CRISPR/Cas9 gene editing for the creation of an MGAT1-deficient CHO cell line to control HIV-1 vaccine glycosylation.
Byrne G; O'Rourke SM; Alexander DL; Yu B; Doran RC; Wright M; Chen Q; Azadi P; Berman PW
PLoS Biol; 2018 Aug; 16(8):e2005817. PubMed ID: 30157178
[TBL] [Abstract][Full Text] [Related]
28. Gene editing in CHO cells to prevent proteolysis and enhance glycosylation: Production of HIV envelope proteins as vaccine immunogens.
Li SW; Wright M; Healey JF; Hutchinson JM; O'Rourke S; Mesa KA; Lollar P; Berman PW
PLoS One; 2020; 15(5):e0233866. PubMed ID: 32470085
[TBL] [Abstract][Full Text] [Related]
29. Varicella-zoster virus with a lost gE epitope: evidence for immunological pressure by the human antibody response.
Padilla JA; Grose C
Arch Virol Suppl; 2001; (17):27-39. PubMed ID: 11339548
[TBL] [Abstract][Full Text] [Related]
30. Baculovirus Vector-Based Varicella-Zoster Virus Vaccine as a Promising Alternative with Enhanced Safety and Therapeutic Functions.
Lee C; Kim M; Chun J; Kim S; Yoon D; Lee H; Bang H; Lee HJ; Park H; Kim YB
Vaccines (Basel); 2024 Mar; 12(3):. PubMed ID: 38543967
[TBL] [Abstract][Full Text] [Related]
31. Exploring the N-Glycosylation Profile of Glycoprotein B from Human Cytomegalovirus Expressed in CHO and
Smargiasso N; Nader J; Rioux S; Mazzucchelli G; Boutry M; De Pauw E; Chaumont F; Navarre C
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370181
[TBL] [Abstract][Full Text] [Related]
32. Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults.
Chlibek R; Pauksens K; Rombo L; van Rijckevorsel G; Richardus JH; Plassmann G; Schwarz TF; Catteau G; Lal H; Heineman TC
Vaccine; 2016 Feb; 34(6):863-8. PubMed ID: 26432913
[TBL] [Abstract][Full Text] [Related]
33. Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers.
Go EP; Ding H; Zhang S; Ringe RP; Nicely N; Hua D; Steinbock RT; Golabek M; Alin J; Alam SM; Cupo A; Haynes BF; Kappes JC; Moore JP; Sodroski JG; Desaire H
J Virol; 2017 May; 91(9):. PubMed ID: 28202756
[TBL] [Abstract][Full Text] [Related]
34. Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant.
Wen Y; Trinh HV; Linton CE; Tani C; Norais N; Martinez-Guzman D; Ramesh P; Sun Y; Situ F; Karaca-Griffin S; Hamlin C; Onkar S; Tian S; Hilt S; Malyala P; Lodaya R; Li N; Otten G; Palladino G; Friedrich K; Aggarwal Y; LaBranche C; Duffy R; Shen X; Tomaras GD; Montefiori DC; Fulp W; Gottardo R; Burke B; Ulmer JB; Zolla-Pazner S; Liao HX; Haynes BF; Michael NL; Kim JH; Rao M; O'Connell RJ; Carfi A; Barnett SW
PLoS One; 2018; 13(4):e0194266. PubMed ID: 29698406
[TBL] [Abstract][Full Text] [Related]
35. Structural and immunological characterization of the N-glycans from the major yellow jacket allergen Ves v 2: the N-glycan structures are needed for the human antibody recognition.
Seppälä U; Selby D; Monsalve R; King TP; Ebner C; Roepstorff P; Bohle B
Mol Immunol; 2009 Jun; 46(10):2014-21. PubMed ID: 19375166
[TBL] [Abstract][Full Text] [Related]
36. Comparative preclinical evaluation of AS01 versus other Adjuvant Systems in a candidate herpes zoster glycoprotein E subunit vaccine.
Fochesato M; Dendouga N; Boxus M
Hum Vaccin Immunother; 2016 Aug; 12(8):2092-2095. PubMed ID: 26933767
[TBL] [Abstract][Full Text] [Related]
37. Purification and characterization of recombinant varicella-zoster virus glycoprotein gpII, secreted by Chinese hamster ovary cells.
Jacquet A; Massaer M; Haumont M; Houard S; Deleersnyder V; Place M; Bollen A; Jacobs P
Protein Expr Purif; 1995 Feb; 6(1):91-8. PubMed ID: 7756843
[TBL] [Abstract][Full Text] [Related]
38. Immune Responses to Varicella-Zoster Virus Glycoprotein E Formulated with Poly(Lactic-co-Glycolic Acid) Nanoparticles and Nucleic Acid Adjuvants in Mice.
Wang Y; Qi J; Cao H; Liu C
Virol Sin; 2021 Feb; 36(1):122-132. PubMed ID: 32757147
[TBL] [Abstract][Full Text] [Related]
39. Ionizable Lipid Nanoparticles Enhanced the Synergistic Adjuvant Effect of CpG ODNs and QS21 in a Varicella Zoster Virus Glycoprotein E Subunit Vaccine.
Luan N; Cao H; Wang Y; Lin K; Liu C
Pharmaceutics; 2022 Apr; 14(5):. PubMed ID: 35631559
[TBL] [Abstract][Full Text] [Related]
40. Truncated glycoprotein E of varicella-zoster virus is an ideal immunogen for Escherichia coli-based vaccine design.
Chen T; Sun J; Zhang S; Li T; Liu L; Xue W; Zhou L; Liang S; Yu Z; Zheng Q; Yu H; Cheng T; Zhang J; Gu Y; Li S; Xia N
Sci China Life Sci; 2023 Apr; 66(4):743-753. PubMed ID: 36790656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
